Valentech
Valentech Pharma is a Colombian pharmaceutical company that licenses, registers, and commercializes rare disease and high-specialty therapies across four Latin American countries for global pharma partners including BioMarin, Daewoong, and Sarepta.
- Company typePrivate
- Founded2011
- HeadquartersBogotá, Colombia
- Headcount11–50
- GTM typeB2B
- OfferingServices
What Valentech does
Valentech Pharma is a privately held pharmaceutical licensing, import, and commercialization company headquartered in Bogotá, Colombia, founded in 2011. The company specializes in rare and orphan diseases across eight high-specialty therapeutic areas: rare cancers, endocrinology, congenital metabolic errors, gastrohepatology, hematology, nephrology, pulmonology, and neuropediatrics. It operates in four Latin American countries — Colombia (home market), Ecuador (since 2022), Peru (since 2024), and Panama (since 2025) — through dedicated offices in Bogotá, Quito, Lima, and Panama City.
Valentech's business model is a one-stop-shop distribution platform: it signs licensing agreements with international pharmaceutical companies (over 10 named partners including BioMarin, Daewoong, Sarepta, Orphalan, Clinuvel, Esteve, Theravia, Biocodex, and Kamada), handles local regulatory registration and importation, then commercializes the products through its own field sales infrastructure targeting specialty physicians, hospitals, and rare disease patients. Revenue is generated through licensing royalties and distribution margins on pharmaceutical product sales; pricing is negotiated on a per-contract basis and not publicly disclosed.
Valentech has built a digital ecosystem supporting its core distribution business: Valentech Access (a platform managing compassionate use and expanded access programs), Valentech Academy/Universidad Valentech (a Moodle-based e-learning platform for medical professionals), and clinical decision-support tools including the Hipercolesterolemia Familiar calculator and the Pheburane dosing calculator. The company holds compliance certifications (ISO 9001, ISO 27001, SOC 2, GDPR, CCPA) and formal Colombian regulatory policies (SAGRILAFT, PTEE), and operates a Patient Support Program with dedicated pharmacovigilance infrastructure. The August 2025 $24.5 million agreement with Daewoong Pharmaceutical for Nabota distribution represents its largest disclosed commercial contract and signals expansion beyond orphan drugs into aesthetics and therapeutics.
Valentech firmographics
Firmographics- Name
- Valentech
- Legal name
- Valentech Pharma
- Website
- https://valentechforlife.com
- Company type
- Private
- Founded year
- 2011
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Valentech Pharma is a Colombian pharmaceutical company that licenses, registers, and commercializes rare disease and high-specialty therapies across four Latin American countries for global pharma partners including BioMarin, Daewoong, and Sarepta.
- Ownership category
- akta.pro rank
Valentech industry classification
Industry- Product category
- Specialty Pharmaceutical Distribution
- NAICS
- Drugs and Druggists' Sundries Merchant Wholesalers (42421), Drugs and Druggists' Sundries Merchant Wholesalers (424210)
- SIC
- Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)
- akta.pro primary industry
- Specialty Pharmacy & Biologics Distribution (CRAOAHAD)
Keywords
Where Valentech is headquartered
LocationHeadquarters
- HQ city
- Bogotá
- HQ country
- Colombia
- HQ region
- Latin America
Offices4 records
Markets served
Valentech business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Supply Chain, Marketing or Sales, Technology or R&D, Infrastructure
Revenue model
- Pharmaceutical Licensing and Distribution: Valentech Pharma generates revenue through licensing agreements with international pharmaceutical companies to register, import, and commercialize innovative therapies for rare and high-specialty diseases in Latin American markets. The company also signed a $24.5 million export deal with Daewoong Pharmaceutical to distribute Nabota (botulinum toxin) in Colombia, expanding into the Latin American aesthetics and therapeutics market.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels5 records
Valentech product offering
Product offeringCore offering
Valentech Pharma is a pharmaceutical licensing, import, and commercialization company that registers, imports, and distributes innovative therapies for rare and orphan diseases in Colombia, Ecuador, Peru, and Panama. It partners with international pharmaceutical companies to bring high-specialty treatments to Latin America in therapeutic areas including rare cancers, endocrinology, congenital metabolic errors, gastrohepatology, hematology, nephrology, pulmonology, and neuropediatrics.
Product overview
Valentech Pharma is a pharmaceutical distribution company specializing in orphan/rare diseases and high-specialty medications across Latin America. The company operates a portfolio of platforms including Valentech Access (digital medication access management), Valentech Academy/Universidad Valentech (e-learning for medical professionals), and clinical tools such as the Hipercolesterolemia Familiar Calculator and Pheburane Calculator. They license, register, import, and commercialize innovative therapies from global pharmaceutical partners, focusing on therapeutic areas including rare cancers, endocrinology, congenital metabolism errors, gastrohepatology, hematology, nephrology, pulmonology, and neuropediatrics. Their Patient Support Program provides accompaniment services to patients and families affected by rare diseases.
Differentiator
Problem solved
Functional benefit
Brands
- Valentech Academy: Online learning platform providing practical and complete medical education for healthcare professionals.
- Valentech Access
- Universidad Valentech
Products and services
- Licensing, Import, and Commercialization of Rare Disease Therapies Core service through which Valentech signs licensing and distribution agreements with international pharmaceutical companies to register, import, and commercialize innovative therapies for rare and high-specialty diseases in Latin American markets, serving patients with rare cancers, endocrinology disorders, congenital metabolic errors, gastrohepatology, hematology, nephrology, pulmonology, and neuropediatric conditions.
- Valentech Access Digital platform that manages transparently, securely, and efficiently the access of patients to special medications in compassionate use situations or under early/expanded access programs. Used by healthcare providers and patients seeking access to innovative therapies.
- Valentech Academy (Universidad Valentech) E-learning platform providing practical and comprehensive medical education for healthcare professionals on rare diseases and specialized treatments, available through the Moodle-based portal at university.valentechforlife.com.
- Hipercolesterolemia Familiar Calculator (HFHO) Online diagnostic tool that enables physicians to calculate familial hypercholesterolemia diagnostic criteria for patients, supporting clinical decision-making for this rare lipid disorder.
- Pheburane Dosing Calculator Dosing calculator tool (version 3.0) that supports physicians in determining correct Pheburane (sodium phenylbutyrate) dosing for patients with urea cycle disorders.
- Patient Support Program Service program providing information, guidance, and accompaniment to patients with rare diseases and their caregivers across Latin America, with dedicated contact channels and email support ([email protected]).
- Pharmacovigilance Service (Farmacovigilancia) Adverse event reporting and ongoing drug safety monitoring service provided to pharmaceutical partners and regulatory authorities across Valentech's commercial markets.
Companies that use Valentech
Customer profileNamed customers1 record
Segments3 records
Ideal customer profiles3 records
Valentech technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Valentech partnerships and signals
Strategic signalPartnerships
Nine partnerships are on record, tiered core and minor.
- Daewoong PharmaceuticalcoreDaewoong Pharmaceutical signed a $24.5 million export deal with Valentech Pharma to sell its botulinum toxin Nabota in Colombia. This agreement aims to expand Nabota's presence in Latin America's fast-growing aesthetics market, following similar market entries in Brazil, Mexico, and Argentina. Valentech serves as the local distribution and commercialization partner for Daewoong's products in Colombia.
- BioMarincoreBioMarin is listed as one of Valentech Pharma's key pharmaceutical partners. Valentech represents and commercializes BioMarin's innovative rare disease therapies in Latin American markets.
- Sarepta TherapeuticscoreSarepta Therapeutics is listed as one of Valentech Pharma's key pharmaceutical partners. Valentech represents and commercializes Sarepta's rare disease therapies including treatments for Duchenne muscular dystrophy in Latin America.
- OrphalancoreOrphalan is listed as a key partner of Valentech Pharma, representing the company's portfolio of treatments for rare diseases in Latin America.
- EsteveminorEsteve is listed as one of Valentech Pharma's pharmaceutical partners, representing treatments for rare diseases in Latin America.
- TheraviaminorTheravia is listed as a pharmaceutical partner of Valentech Pharma, collaborating on rare disease treatments in the Latin American market.
- ClinuvelminorClinuvel is listed as a pharmaceutical partner of Valentech Pharma, representing treatments for rare diseases in Latin America.
- BiocodexminorBiocodex is listed as a pharmaceutical partner of Valentech Pharma, collaborating on rare disease treatments in the Latin American market.
- KamadaminorKamada is listed as a pharmaceutical partner of Valentech Pharma, representing treatments for rare diseases in Latin America.
Scale indicators5 records
Recent moves9 records
Expansion highlights5 records
Valentech competitors and assessment
Company assessmentBroad incumbents
- Eurofarma: Largest multinational pharmaceutical company in Latin America, headquartered in Brazil, with a broad portfolio including specialty and rare disease products. Acts as a broad incumbent with overlapping distribution and commercialization capabilities across LatAm.
- Recordati Rare Diseases: Global specialty pharmaceutical group with a dedicated rare disease business commercializing treatments for metabolic, endocrine, and ultra-rare conditions worldwide. Comparable in therapeutic focus and in operating a specialty/rare-disease distribution model, but at a global rather than LatAm-localized scale.
- Swedish Orphan Biovitrum (Sobi): Global specialty biopharma focused on rare diseases (haematology, immunology, specialty care). Comparable therapeutic-area focus and partner-driven commercialization model, with growing LatAm presence. Larger and more globalized than Valentech.
- Alexion / AstraZeneca Rare Disease: Global leader in rare disease therapeutics (now part of AstraZeneca), commercializing treatments across haematology, nephrology, neurology, and metabolic rare diseases. Comparable in therapeutic focus areas where Valentech operates and in expanding access to LatAm via local partnerships.
- Sanofi Genzyme (Rare Diseases): Global rare disease franchise (formerly Genzyme) commercializing therapies for rare and specialty conditions with established LatAm operations. Overlaps with Valentech on therapeutic areas such as rare metabolic, hematology, and neuropediatric conditions, but at a much larger scale.
Direct peers
- Megalabs: Latin American pharmaceutical company with presence in 18+ countries covering branded generics, specialty, and rare disease products. Comparable as a multi-country LatAm commercialization partner for global pharma, with overlap in therapeutic categories such as gastro/hepato and endocrinology.
- Biopas: Latin American specialty pharmaceutical company focused on rare diseases, specialty therapies, and biologics across multiple LatAm countries. Operates a very similar licensing, registration, importation, and commercialization model with global pharma partners, making it the closest functional peer to Valentech.
- Knight Therapeutics (formerly Grupo Biotoscana / GBT Pharma): Specialty pharmaceutical distributor headquartered in LatAm (acquired by Knight Therapeutics), commercializing innovative therapies including rare disease products across the region. Highly comparable model of licensing and distributing partner pharma products across multiple LatAm markets.
Regional players
- Raffo Laboratorios: Argentine pharmaceutical company with branded specialty, oncology, and rare disease products distributed across several LatAm countries. Comparable regional specialty pharmaceutical distributor with overlapping therapeutic categories, though headquartered and primarily operating in the Southern Cone.
- Hypera Pharma: Largest Brazilian pharmaceutical company by market cap, with branded prescription, specialty, and consumer health products across LatAm. Comparable as a scaled LatAm pharmaceutical commercialization platform, though primarily Brazil-focused rather than Andean-region focused like Valentech.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Valentech social profiles
Digital presenceValentech compliance and trust
Trust signalCompliance5 records
Valentech financial estimates
Financial estimateRevenue estimate
Valuation estimate
Valentech leadership team
Management profileNumber of profiles
Valentech funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Valentech M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Valentech
What does Valentech do?
Valentech Pharma is a pharmaceutical licensing, import, and commercialization company that registers, imports, and distributes innovative therapies for rare and orphan diseases in Colombia, Ecuador, Peru, and Panama. It partners with international pharmaceutical companies to bring high-specialty treatments to Latin America in therapeutic areas including rare cancers, endocrinology, congenital metabolic errors, gastrohepatology, hematology, nephrology, pulmonology, and neuropediatrics.
Is Valentech a public or private company?
Valentech is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Valentech founded?
Valentech was founded in 2011. It employs 11 to 50 people.
Where is Valentech based?
Valentech is headquartered in Bogotá, Colombia, in the Latin America region.
How does Valentech make money?
One revenue line is on record: pharmaceutical Licensing and Distribution.
Who are Valentech's main competitors?
Broad incumbents on record are Eurofarma, Recordati Rare Diseases, Swedish Orphan Biovitrum (Sobi), Alexion / AstraZeneca Rare Disease and Sanofi Genzyme (Rare Diseases). Direct peers are Megalabs, Biopas and Knight Therapeutics (formerly Grupo Biotoscana / GBT Pharma). Regional players are Raffo Laboratorios and Hypera Pharma.
Does Valentech have an API?
No public API is recorded for Valentech.
What industry is Valentech in?
Valentech's product category is Specialty Pharmaceutical Distribution. Its primary akta.pro industry code is CRAOAHAD, Specialty Pharmacy & Biologics Distribution. Its NAICS code is 42421 and its SIC code is 5122.